Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “HISTAMINE LIBERATION”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 559 records · Page 31Linked to original sources
PubMedDate not supplied

Histamine releasing lymphokines: a new approach to some old problems.

Studies carried out in recent years reveal that some endogenous substances can degranulate mast cells and basophils. Lymphokines produced in vitro by T lymphocytes in presence of an antigen or a mitogen, which are capable of provoking histamine liberation in basophils and mast cells have been described. Lastly the mechanisms for histamine release not mediated by IgE in bronchial asthma and which can be mediated by these factors, is discussed.

Animals↗
PubMed1976

Chemical mediators of anaphylaxis (histamine, 5-HT, and SRS-A) released from horse lung and leukocytes in vitro.

Horses were sensitized to bovine plasma in Freund's complete adjuvant. Leukocytes, separated from venous blood, yielded histamine upon incubation with bovine plasma. Ioslated lung fragments incubated with bovine plasma liberated histamine and 5-HT, but not SRS-A. Pulmonary veins obtained from the same animals contracted to histamine, 5-HT and to antigen (Schultz-Dale reaction). Histamine and 5-HT probably contribute to immediate-type hypersensitivity in horses whereas the role of SRS-A is not proved.

Anaphylaxis↗
PubMed1992

Assessment of histamine release from basophils in whole blood by benzylpenicilloyl poly-L-lysine in penicillin-sensitized patients.

Histamine release from basophil granulocytes in whole blood by benzylpenicilloyl poly-L-lysine (PPL) was investigated in 7 patients with penicillin allergy. All patients presented with systemic immediate hypersensitivity reactions after i.v. administration of penicillin G. Total histamine (of 7 patients) ranged from 27.5 ng/ml to 62.1 ng/ml (mean 43.2 ng/ml). The spontaneous histamine release ranged from 0.15% to 5.1% (mean 1.8%) of the total content. Addition of PPL in various concentrations resulted in values between 0.8 and 9.6%. Although PPL is a reliable allergen for prick- and intradermal testing in the diagnosis of penicillin allergy--demonstrating a histamine liberation in the skin--the in vitro experiment using the same allergen showed no histamine release above 10%. Using a threshold of 5% out of 7 patients, 4 (57%) would show a positive histamine release. Therefore it might indicate that in penicillin allergy a threshold of 5% must be used. In addition, basophils in whole blood and skin mast cells may be activated differently.

Adolescent↗
PubMed1992

A naturally occurring opioid peptide from cow's milk, beta-casomorphine-7, is a direct histamine releaser in man.

beta-Casomorphine-7, a naturally occurring product of cow's milk with opiate-like activity, was studied for possible direct histamine liberation activities in humans. It was found to cause concentration-dependent in vitro histamine release from peripheral leukocytes of healthy adult volunteers. Intradermal injection of beta-casomorphine-7 induced a wheal and flare reaction in the skin similar to histamine or codeine. Oral pretreatment with the H1 antagonist terfenadine significantly inhibited the skin responses to beta-casomorphine-7. The intradermal injection of an opiate receptor antagonist, naloxone, inhibited in vitro histamine release and skin reactions only in a 100-fold excess over beta-casomorphine-7. These findings suggest that beta-casomorphine-7 can be regarded as a noncytotoxic, direct histamine releaser in humans. The clinical relevance of these findings deserves further studies.

Adult↗
PubMed1999

Cardiotoxicity of histamine and the possible role of histamine in the arrhythmogenesis produced by certain antihistamines.

Since 1990 it has repeatedly been reported that some histamine H1 receptor antagonists (e.g. terfenadine and astemizole) are able to produce ventricular arrhythmias (e.g. torsade de pointes) when they are given at dosages above the therapeutic range and/or administered together with cytochrome P-450 3A4 inhibitors, such as ketoconazole or erythromycin. Although the mechanism by which these arrhythmias are produced remains unclear, the recently reported ability of these drugs to block outward K+ currents has been suggested as the cause of their arrhythmogenic effects. Alternatively, we have observed that some H1 antihistamines, including terfenadine and astemizole, are able to release histamine from guinea-pig cardiac mast cells. Thus, we have proposed that the liberated histamine, acting through an H2 receptor-stimulating mechanism, can prolong the action potential duration and hence induce arrhythmogenic effects. This paper describes experimental observations supporting the hypothesis that some H1 antihistamines can induce severe cardiac arrhythmias via the local release of histamine.

Animals↗
PubMed1982

Influence of various drugs on the variations of blood pressure, hematocrit and plasma histamine caused by neurotensin and compound 48/80 in rats.

Intravenous injections of neurotensin (NT) (0.5, 1 and 2 nmoles kg-1) evoked dose-dependent increases in histaminemia and hematocrit, and marked hypotensive effect, in anesthetized rats. The increase of plasma histamine was rapid in onset (within sec), peak plasma histamine being reached in less than 2 min. The decline of plasma histamine was gradual and almost complete 15 min after injection of NT. The hematocrit increased slowly, maximum values being obtained 5-10 min after injection of NT, and it persisted throughout the period of observation. The hypotensive effect of NT was rapid in onset and of prolonged duration. Compound 48/80, a well known histamine liberator and mast cell depletor, produced variations of blood pressure, of hematocrit and of plasma histamine very similar to those elicited by NT. Pretreatment of rats with cromoglycate, a well known mast cell stabilizer, or with dexamethasone, inhibited markedly the changes of histaminemia, of hematocrit and of blood pressure evoked by NT and compound 48/80. The results clearly suggest that the effects of NT on blood pressure and on vascular permeability in rats are mediated to some extent by mast cell histamine. Hexamethonium, a ganglion blocker, inhibited slightly the effect of NT on histaminemia but it did not block NT-induced changes of hematocrit. However, the hypotensive effect of NT was severely blocked in hexamethonium-treated rats. These results were interpretated as an indication that hexamethonium prevents NT-induced hypotension not merely by reducing the mobilization of mast cell histamine by NT but most likely by interfering with the mechanism by which NT and/or its mast cell mediators produce their effects on blood pressure.

Animals↗
PubMed1982

Mast cell receptors controlling histamine release: influences on the mode of action of drugs used in the treatment of adverse drug reactions.

In drug-induced allergic diseases of the immediate type (anaphylactic and anaphylactoid reactions), the primary target cells are tissue mast cells, which discharge their granular content upon interaction with different secretagogues (immunological releasers; histamine liberators) on specific plasma membrane receptors. Experiments are reviewed here which report that IgE-mediated histamine release from mast cells, and the secretion of histamine induced by non-immunological secretagogues (dextran; compound 48/80; acetylcholine) are blocked by beta-adrenoceptor and H2-receptor agonists, their inhibiting effect being surmountable by beta-adrenoceptor blocking drugs and by anti-H2-antihistamines. Specific radioligands ([3H]-dihydroalprenolol; [3H]-cimetidine) binding to rat mast cell membranes points to the possibility that inhibition of histamine release is brought about by the activation of mast cell beta-adrenoceptors and H2-receptors. Drugs used in therapy of anaphylactic or anaphylactoid reactions may act either on tissue receptors, competing with released mediators, or by inhibiting the release of allergic mediators from mast cells, on activation of specific receptors located in mast cell plasma membranes.

Acetylcholine↗
PubMed1983

Plasma histamine concentrations and complement activation during house dust mite-provoked bronchial obstructive reactions.

Lung function and histamine levels in peripheral venous plasma samples were followed after challenge with house dust mite allergen. In eight patients the mean maximal histamine concentration showed a significant rise during the early obstructive reaction when compared with the concentrations at similar time intervals after inhalation of a control solution. In nine other patients treatment with disodium cromoglycate (DSCG) caused a significant fall in plasma histamine concentrations indicating that histamine liberation plays a role during the early obstructive reaction and was released from the lung compartment. Histamine during early obstructive reactions compared with the pre-inhalation values did show a rise in mean maximal histamine concentration (1.5-4.1 ng/ml) but this was statistically not significant. During the late reaction neither significant increase in histamine nor inhibition by DSCG was found. Measurement of complement degradation products did not support the role of complement activation during either early or late bronchial obstructive reactions.

Adolescent↗
PubMed1993

Immediate allergic and nonallergic reactivity of the airways in Ascaris skin-sensitive sheep.

Immediate airway reactivity to Ascaris suum allergen was compared with the responses to nonallergic airway challenge using histamine and acetylcholine in sheep with positive skin reactions to the allergen. In a control group of 6 sheep with negative skin test responses, allergen aerosol inhalation and allergen extract infusion only caused minor changes in mechanics of breathing as well as in arterial plasma histamine concentration. Nearly 40% of the animals with a positive skin test responded to allergen inhalation with an acute airway obstruction, whereas all animals bronchoconstricted after allergen infusion. Bronchoconstriction was associated with an increase in arterial plasma histamine concentrations. The difference between the two groups of skin test-positive sheep seems to be due to the amount of histamine liberation after allergen exposure. Allergen infusion caused a more severe increase of airway resistance and plasma histamine levels in animals responding to allergen inhalation than in animals responding to allergen infusion only. Similar responses were obtained in both groups after inhalation and infusion of histamine and acetylcholine. Since the slope of the responses (dEdyn/dHi.Pl.) was similar in both groups of animals we conclude that the sensitivity of receptors is similar in responders to allergen inhalation and in animals responding to allergen infusion only.

Acetylcholine↗
PubMed1992

Inhibitory effect of loratadine and clemastine on histamine release in human skin.

The inhibitory effect of the two H1 antagonists clemastine and loratadine on histamine release in human skin was studied in 15 volunteers. The antihistamines and placebo were administered orally (clemastine 2 mg twice a day, loratadine 10 mg once a day) for 5 days according to a double-blind, crossover design. Clemastine caused a significant sedation in comparison with placebo, whereas there was no difference between loratadine and placebo in this respect. After 5 days' medication, flare reaction was induced by intradermal injection of histamine and the histamine liberator compound 48/80. The antihistamine dosages were approximately equipotent and inhibited the flare response induced by histamine to about the same extent, whereas the flares induced by compound 48/80 were still more inhibited by both drugs. The results indicate that clemastine and loratadine not only inhibit histamine effects at H1 receptor level, but have additional suppressive effects, probably due to inhibition of mast cell degranulation. The simple, virtually noninvasive, in vivo technique described in this paper does not require chemical analysis of the released mediators and could be used to screen 'mast cell stabilizing' effects of various antihistamines.

Adolescent↗
PubMed1977

The effect of beta-adrenergic blocking drugs and inhibitors of phosphodiestease on histamine release from isolated mast cells.

Differences in the histamine liberation from isolated rat mast cells after beta-adrenergic blocking drugs were demonstrated. In equimolar concentrations histamine release was induced by Kö 1124, Kö 1500, Kö 1560, Kö 1561 and propranolol. Alprenolol, oxprenolol, propranolol, and trimepranol significantly decreased thehistamine release induced by compound 48-80. The release of granules from cells was inhibited quantitatively more than the release of histamine. This enabled us to surmise the selective effect of beta-adrenergic blocking drugs on cell membranes of mast cells. The possible mechanisms of release reaction are discussed.

Adrenergic beta-Antagonists↗
PubMed1980

H1 + H2-receptor antagonists for premedication in anaesthesia and surgery: a critical view based on randomized clinical trials with Haemaccel and various antiallergic drugs.

Histamine release by drugs used in anaesthesia and surgery has been often demonstrated in human volunteers, but only occassionally in patients. Three questions arose from these studies. (1) Is the incidence of histamine release high in patients during routine anaesthesia and surgery? (2) Can the clinical effects of histamine release in man be prevented by H1 + H2-receptor antagonists? (3) Are there any side-effects of such a premedication? These problems were investigated in patients and volunteers by randomized controlled clinical trials using only one of the histamine-liberating drugs in man, the plasma substitute Haemaccel. This drug was chosen because it causes a reproducible histamine release in man and because its mechanism of action in man is largely known. (1) Out of 600 orthopaedic patients 30 (5%) showed anaphylactoid reactions following Haemaccel infusion. 26 of these had a histamine release of more than 1 ng histamine/ml plasma. Using predictive values this gives an efficiency of the test by nearly 98%. (2) In volunteers the combination of an H1-plus H2-receptor antagonist (dimethypyrindene and cimetidine) completely prevented the clinical effects of histamine release by Haemaccel (9 allergoid and anaphylactoid reactions in the control group, none in the H1 + H2-group). The incidence of histamine release, however, remained unchanged. (3) The premedication was found to release histamine itself. Cimetidine was effective when given alone but especially in combination with chlorpheniramine (4 events out of 7 applications). The clinical side-effects of these premedication were mild since apparently the free histamine was largely blocked at the receptor sites. It is concluded that premedication with a combination of H1- and H2-receptor antagonists is indicated due to the high incidence of histamine release during anaesthesia and surgery induced by various drugs and treatments. Such premedication is effective but associated with mild side-effects. For this reason more extended clinical trials with dimethpyrindene plus cimetidine in patients are necessary before this premedication can be generally recommended.

Adolescent↗
PubMed1990

Platelet activating factor does not release histamine from human dispersed cutaneous mast cells.

Histamine H1-antagonists inhibit the weal-and-flare responses to the intradermal injection of platelet activating factor (PAF) in humans, and PAF response is reduced in histamine-depleted skin sites. This indicates that mast cell histamine release is likely to be the mechanism of this response. We have therefore studied the interaction of PAF with cutaneous mast cells by observing whether it releases histamine directly from human dispersed foreskin mast cells, potentiates the activity of known mast cell stimulants or liberates histamine releasing factors (HRFs) from human platelets and leucocytes to release mast cell histamine by an indirect mechanism. At a concentration of 100 microM both PAF C18 and PAF C16 caused near maximal release (83.5 +/- 4.3% and 88.2 +/- 4.5% respectively) of the total histamine content of the cell. This release was not inhibited in the absence of extracellular Ca2+, by the lack of metabolic energy or in the presence of the PAF antagonists WEB 2086 (100 nM-3 microM) or BN 52021 (100 nM-10 microM). These results indicate a cytotoxic mechanism of histamine release by PAF 100 microM. PAF (10 nM-1 microM) failed to potentiate the mast cell-stimulating activity of anti-IgE, calcium ionophore A23187 or substance P and it did not induce the release of HRFs for skin mast cells when incubated with platelets and leucocytes in concentrations up to 1 microM.

Antibodies, Anti-Idiotypic↗
PubMed1991

The effect of platelet-activating factor on histamine release from guinea pig peritoneal mast cells.

The effect of platelet-activating factor (PAF) on histamine release from the peritoneal mast cells of male guinea pigs at 4 weeks of age and one week of age (weaning) was investigated. PAF as well as compound 48/80 and concanavalin A were not found to release histamine from the mast cells of either age of guinea pigs. On the other hand, Ca2+ ionophore A23187 showed a significant, concentration-dependent histamine release from the mast cells obtained from guinea pig of either age group. PAF (3 x 10(-7) - 3 x 10(-6) g/ml) significantly inhibited the histamine release induced by Ca2+ ionophore A23187 from the mast cells of guinea pigs at one week of age, but not from those of the older ones. Such an inhibition was not seen with lyso-PAF in either age group. CV-3988, a PAF antagonist, neutralized the inhibitory effect of PAF on the A23187-induced histamine release from the mast cells of guinea pigs at one week of age. These results indicate that PAF does not have a histamine-liberating action on guinea pig peritoneal mast cells, and that PAF inhibits the effect of A23187 on histamine release from mast cells through activation of PAF receptor in guinea pigs at one week of age.

Animals↗
PubMed1991

Atenolol, exaprolol and mast cell membranes.

Lipophilic exaprolol and hydrophilic atenolol differ in their interaction with mast cell membranes. Exaprolol, as compared with atenolol, significantly decreased 32P incorporation into, but increased arachidonic acid liberation from, membrane phospholipids. Moreover, exaprolol significantly decreased phosphate incorporation in compound 48/80 and ConA-PS treated cells and decreased thromboxane formation in stimulated cells. On the other hand, atenolol decreased significantly only arachidonate liberation from stimulated mast cells. These results corroborate to some extent the effect of exaprolol and atenolol on histamine liberation which correlates with their membrane perturbing properties.

Adrenergic beta-Antagonists↗
PubMed1988

Cellular localization of ovarian histamine, its cyclic variations, and histaminergic effects on ovulation in the rat ovary perfused in vitro.

Mast cells, visualized with toluidine blue staining and the Falck-Hillarp fluorescence technique, were mainly located around large blood vessels in the hilus region of the ovary in adult rats and in immature rats treated with PMSG. Histamine concentration in the rat ovary was significantly reduced after the LH surge in PMSG-treated animals, corresponding to a reduced number of ovarian mast cells. No marked change in the number of mast cells and histamine concentration was found in adult rats during the oestrous cycle. Histamine as well as the H1-agonist, 2-methylhistamine, and the H2-agonist, 4-methylhistamine, induced ovulations in the isolated perfused rat ovary. Ovulation rates were significantly lower than those evoked by LH. The histamine liberator, Compound 48/80, induced ovulations which were blocked by the combined effect of the H1- and H2-histamine receptor antagonists, cimetidine and pyrilamine. The anti-degranulating agent, disodium cromoglycate, did not block ovulations induced by Compound 48/80. The results show that the level of ovarian histamine, which is primarily stored in mast cells, can be influenced by PMSG treatment, and that the amine is able to induce ovulations in gonadotrophin-primed rats by an effect mediated by both H1 and H2 receptors.

Animals↗
PubMed1992

Studies on the relationship between xanthine oxidase and histamine release during intestinal ischemia-reperfusion.

Recent studies have demonstrated a connection between xanthine oxidase-generated reactive oxygen intermediates and histamine release during ischemia-reperfusion. In the present work, the effect of modulation of the endogenous histamine level on the xanthine oxidase activity was examined during the reperfusion of a canine ileal segment following a 2 hr of complete ischemia. The xanthine oxidase activity and the plasma histamine level peaked simultaneously at the beginning of reperfusion, reaching mean values of 14.9 nmol/ml/min and 12.1 nmol/l, respectively. Pretreatment with aminoguanidine, a blocker of diamine oxidase (histaminase), resulted in significantly higher levels of histamine during reperfusion, but this elevation was not accompanied by a further increase in xanthine oxidase activity. Pretreatment with the mast cell stabilizer cromolyn significantly diminished the rise in plasma histamine level, with an unchanging activity of xanthine oxidase. No significant alteration could be observed in the postocclusive activity of xanthine oxidase following the intra-arterial administration of 0.5, 1, or 5 nmol of histamine during the last 10 min of the ischemic period. These data suggest that the amount of histamine liberated during reperfusion does not result in a further increase in the xanthine oxidase activity. The release of histamine is not a cause, but rather an effect of the elevated activity of intestinal xanthine oxidase.

Animals↗
PubMed1988

[Cardiovascular reactions and histamine release following atracurium--a problem of dosage?].

All muscle relaxants can induce allergic or pseudo-allergic reactions. The medium-long-acting, nondepolarizing muscle relaxant atracurium has been shown to be a potent histamine liberator. Up to now it is unknown if a clinical dosage of atracurium exists where no clinically relevant histamine release occurs. In a prospectively controlled study we therefore investigated the effects of different dosages of atracurium on cardiovascular reactions and histamine release.

Adult↗